Viridian Therapeutics Reports Q2 2026 Quarterly Results

What Happened
Viridian Therapeutics, Inc. (VRDN) announced its financial results for the quarter ended June 30, 2026 in a press release dated August 6, 2026. The company filed a Form 8-K on August 6, 2026 to report these results (Item 2.02), and the press release is attached to the filing as Exhibit 99.1.

Key Details

• Press release reporting quarterly financial results dated August 6, 2026.
• Results cover the quarter ended June 30, 2026 (Q2 2026).
• The Form 8-K was furnished under Item 2.02 (Results of Operations and Financial Condition) and includes Exhibit 99.1.
• Item 9.01 lists exhibits, including the press release (Exhibit 99.1) and the Inline XBRL cover page.

Why It Matters
This filing provides Viridian’s latest quarterly operating and financial information—important for investors tracking revenue, expenses, cash runway, and any updates that could affect valuation or near-term plans. The 8-K does not report executive changes, mergers, or other material events beyond the quarterly results; investors should read the attached press release (Exhibit 99.1) for the specific financial figures and management commentary.